Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02363426 · ClinicalTrials.gov registry record · Phase 3

Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation

A Phase 3 study of Infertility, sponsored by Invaron Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
40
Enrollment target
1
Study location

NCT02363426 is a Phase 3 study of Infertility that has completed, run by Invaron Pharmaceuticals. The registered enrollment target is 40 participants, below the 7,589-participant average among 74 other Infertility trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02363426, a Phase 3 study of Infertility, has completed, sponsored by Invaron Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate intravaginal culture using the medical device INVOcell to generate day 5 blastocysts in comparison to traditional IVF.

Conditions Studied

Interventions

  • DEVICE INVOcell Culture Device
  • DEVICE IVF Incubation

Study Locations (1)

Texas

  • C.A.R.E. - Beford

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2013-01
Est. Completion 2016-01
Phase Phase 3

Sponsor

Invaron Pharmaceuticals

1 total trials

What the Registry Record Tells You About NCT02363426

The ClinicalTrials.gov registry entry for NCT02363426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,589-participant average among 74 other Infertility trials with a reported enrollment target (99% lower). The listed sponsor is Invaron Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 2 interventions - of which INVOcell Culture Device is the first listed.

NCT02363426 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02363426 about?

NCT02363426 is a clinical study titled "Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation". The purpose of this study is to evaluate intravaginal culture using the medical device INVOcell to generate day 5 blastocysts in comparison to traditional IVF.

What is the current status of trial NCT02363426?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2013-01. Estimated completion is 2016-01.

What conditions does trial NCT02363426 study?

This clinical trial studies the following conditions: Infertility.

What interventions are being tested in trial NCT02363426?

The interventions under investigation include: INVOcell Culture Device (DEVICE), IVF Incubation (DEVICE).

Who is sponsoring clinical trial NCT02363426?

This trial is sponsored by Invaron Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02363426 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infertility

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.